ModernMedicine Resource Center More Topics

Targeted Therapy Resource Center

Burnout, biopsy, BPH, and more: Post-AUA reviewUrologist Henry Rosevear, MD, reviews his personal highlights from AUA 2017, along with a few bumps in the road.
Immunotherapy treats Ca based on genetic featureThe FDA has approved pembrolizumab (Keytruda) for treating any solid tumors that exhibit DNA mismatch repair deficiency.
Should RCC immunotherapy continue after progression?Some patients being treated with nivolumab (Opdivo) for advanced renal cell carcinoma may still derive benefit if continued on the immunotherapy after disease progression, according to an analysis of phase III study data.
Urothelial Ca immunotherapy approved for first-line use“Modern immunotherapy is active in advanced urothelial carcinoma and represents the most important advancement in the treatment of this disease in over 30 years,” says investigator Arjun V. Balar, MD.
Has the USPSTF gone far enough with its new PCa grade?Urology Times asked members of our editorial advisory board: Has the USPSTF gone far enough with its new draft recommendation on screening for prostate cancer?
Small molecule RNA inhibitor shows promise in PCaTargeted treatment with a small molecule RNA inhibitor demonstrates promising activity for promoting apoptosis of prostate cancer cells in culture, report investigators from Scripps Florida.
Combination immunotherapy may raise response rate in mRCC“The data from our study show that combination therapy [for metastatic renal cell carcinoma] may offer a much higher response rate with manageable side effects,” says study author Jianjun Gao, MD, PhD.
PCa immunotherapy: Response better when given before ADTAdministering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.
Prostate Ca: Immunotherapy consensus statement publishedStatement authors recommend using immunotherapy prior to an androgen receptor-targeted agent in men with metastatic castration-resistant prostate cancer.
High-grade bladder Ca: New data improve risk stratification“We need to identify those patients with high-grade T1 bladder cancer that are likely to recur or progress… and find additional options to prevent recurrence and progression in these patients,” said Joaquim Bellmunt, MD, PhD, in a presentation at the SUO annual meeting.